Improving Alpha-Emitter Therapy for Neuroendocrine Tumors and Protecting Kidneys
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
['FUNDING_R01'] · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · NIH-11115687
This project looks for better ways to treat neuroendocrine tumors with a special type of radiation therapy, while also keeping kidneys safe.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST NATIONWIDE CHILDREN'S HOSP (nih funded) |
| Locations | 1 site (COLUMBUS, UNITED STATES) |
| Trial ID | NIH-11115687 on ClinicalTrials.gov |
What this research studies
We are working to make a powerful new radiation treatment for neuroendocrine tumors even safer and more effective. This therapy uses alpha-emitters, which have shown great promise in shrinking tumors, but can sometimes affect the kidneys. Our goal is to find the best treatment plan, including the right dose and timing, and to use special medicines that protect the kidneys. We will also use new urine tests to quickly spot any kidney changes, ensuring patients receive the most benefit with the fewest side effects.
Who could benefit from this research
Good fit: Patients with neuroendocrine tumors that express the SSTR2 receptor, who might be candidates for alpha-emitter radioligand therapy, could potentially benefit from this research.
Not a fit: Patients with tumor types that do not express the SSTR2 receptor or those who are not candidates for radioligand therapy may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer alpha-emitter radioligand therapy for patients with neuroendocrine tumors, reducing the risk of kidney damage.
How similar studies have performed: Alpha-emitter radioligand therapies have shown promising tumor response rates in early clinical studies, but this project introduces novel strategies for kidney protection and optimized dosing.
Where this research is happening
COLUMBUS, UNITED STATES
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP — COLUMBUS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZEPEDA-OROZCO, DIANA — RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- Study coordinator: ZEPEDA-OROZCO, DIANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers